TEVA, US8816242098

Teva reports Uvakitug efficacy data. November 3 results matter for Teva stock

Published on 10/23/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Weltruza launched with three approved doses after FDA approval on October 9, 2026. For Teva stock, revenue was USD 4.14 billion before November 3 results.

Targets and upcoming milestones

Gettex listed Uvakitug efficacy data on October 20, 2026.
Teva received Weltruza approval on October 9, 2026, with three doses.
Teva is scheduled to report third-quarter results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Limited (ISIN US8816242098) is heading toward November 3, 2026, quarterly results after a report on Uvakitug efficacy improvements dated October 20, 2026. Gettex listed the long-term extension study update, while the next report will test whether Teva's growth portfolio is translating into earnings.

Three dated catalysts

Teva reported USD 4.14 billion in revenue for the second quarter ended June 30, 2026, up 2.5 percent against the USD 4.04 billion consensus estimate, while adjusted earnings per share reached USD 0.64 versus USD 0.05 expected, according to Earnings Today on July 29, 2026. On October 9, 2026, Teva announced FDA approval for Weltruza, available in three strengths of 318 mg, 425 mg and 531 mg, according to Teva. Barclays then raised its price target from USD 42.00 to USD 47.00 on October 15, 2026, as reported by Benzinga.

What does the target increase signal?

The Barclays target increase represents an 11.90 percent rise from the previous USD 42.00 level. That assessment places greater weight on Teva's innovative medicines and pipeline than on the latest quarter's GAAP loss of USD 576 million, which was reported for the second quarter of 2026.

Dates that shape the next update

Teva will release third-quarter 2026 results on November 3, 2026, at 7:00 a.m. ET and hold its conference call at 8:00 a.m. ET, according to GlobeNewswire. The Gettex event listing also names an R&D Day in New York on November 11, 2026.

Investor perspective

The next disclosure cycle therefore combines a scheduled financial test with a product pipeline narrative. Revenue growth and adjusted earnings were ahead of consensus in the second quarter, but the USD 576 million GAAP loss leaves execution and product uptake central to the next assessment.